As CEO of his own soon-to-be public company, Bill Ackman will use a dual share-class structure that has been considered unfriendly to investors.» Read More
Jim Chanos of Kynikos Associates says he'll continue to bet against Caterpillar and China, as well as a few other names.
With a who's who of bankers and hedge fund titans in attendance, the Robin Hood Foundation's annual gala raised more than $60 million.
U.S. medical firm Allergan rejected the unsolicited takeover offer from Valeant Pharmaceuticals, saying it substantially undervalued the company.
Happy Monday and welcome to another wild and woolly week on Wall Street.
Activist investors are known to make headlines, but surprisingly only a third of the firms that are approached by activists make the overtures public.
Bill Ackman reiterated a popular hedge fund trade by recommending an investment in government-sponsored housing.
The Ira Sohn Investment Conference gets underway, with a bevy of high-profile managers set to give their picks.
Pershing Square on Friday released a short, scathing documentary on Herbalife that detailed the stories of frustrated former distributors.
Mario Gabelli said the partnership of activist investor Bill Ackman and Valeant Pharmaceuticals to try to buy Allergan was unfair.
Happy Friday, which is, of course Jobs Friday. Seems like we just had one of these a month ago.
Bill Ackman and Carl Icahn, whose epic battle on CNBC stunned Wall Street, exchanged pleasantries last week and decided to forgive each other.
Herbalife rallied Monday after the company posted quarterly results that topped expectations. The company also said it is terminating its dividend.
Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Hedge fund manager Bill Ackman promised to pay a disgruntled ex-Herbalife executive as much as $3.60 million over the next 10 years, a report said.
Virtually every Pershing Square Capital investment appears to have made money this year.
One of Valeant's top shareholders on Tuesday threw his support behind its proposed takeover bid for Botox-maker Allergan.
Happy Tuesday. Keep your eye on the prize and watch out for the activist investor looking to snag your Morning Six-Pack.
The bid for botox producer Allergan reveals the "legal scam" that the U.S. tax code has become, CNBC's Jim Cramer says.